These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 2288831)

  • 21. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
    Fries R; Shariat K; von Wilmowsky H; Böhm M
    Circulation; 2005 Nov; 112(19):2980-5. PubMed ID: 16275885
    [TBL] [Abstract][Full Text] [Related]  

  • 22. International study of ketanserin in Raynaud's phenomenon.
    Coffman JD; Clement DL; Creager MA; Dormandy JA; Janssens MM; McKendry RJ; Murray GD; Nielsen SL
    Am J Med; 1989 Sep; 87(3):264-8. PubMed ID: 2672807
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic efficacy of ketanserin, a selective antagonist of the serotonin (5-HT2) receptors, in primary and secondary Raynaud's phenomenon.
    Meloni F; Transi MG; Sciacca V; De Felice C; Bagarone A; Sciacca A
    Angiology; 1987 Jul; 38(7):530-6. PubMed ID: 3619126
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
    Wigley FM; Seibold JR; Wise RA; McCloskey DA; Dole WP
    J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serotonin-induced platelet aggregation predicts the antihypertensive response to serotonin receptor antagonists.
    Gleerup G; Persson B; Hedner T; Winther K
    Eur J Clin Pharmacol; 1993; 44(2):121-5. PubMed ID: 8453957
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and tolerability of a selective alpha(2C)-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: a single-center, double-blind, placebo-controlled, randomized crossover study.
    Wise RA; Wigley FM; White B; Leatherman G; Zhong J; Krasa H; Kambayashi J; Orlandi C; Czerwiec FS
    Arthritis Rheum; 2004 Dec; 50(12):3994-4001. PubMed ID: 15593189
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of 5-hydroxytryptamine-induced and -amplified human platelet aggregation by ketanserin (R 41 468), a selective 5-HT2-receptor antagonist.
    de Clerck F; David JL; Janssen PA
    Agents Actions; 1982 Jul; 12(3):388-97. PubMed ID: 6215842
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative efficacy of ketanserin and pentoxiphylline in treatment of Raynaud's phenomenon.
    Arosio E; Montesi G; Zannoni M; Paluani F; Lechi A
    Angiology; 1989 Jul; 40(7):633-8. PubMed ID: 2662829
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Digital pressure-flow relationships in subjects with Raynaud's phenomenon.
    Wise RA; Wigley FM; Malamet R
    Angiology; 1985 Sep; 36(9):596-602. PubMed ID: 4051252
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of the serotonin antagonists, cyproheptadine, ketanserin and mianserin, on cyclic flow reductions in stenosed canine coronary arteries.
    Bush LR
    J Pharmacol Exp Ther; 1987 Feb; 240(2):674-82. PubMed ID: 3806419
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effectiveness of ketanserin in patients with primary Raynaud's phenomenon. A randomized, double blind, placebo controlled study.
    van de Wal HJ; Wijn PF; van Lier HJ; Skotnicki SH
    Int Angiol; 1987; 6(3):313-22. PubMed ID: 3329207
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of local temperature versus sympathetic tone on digital perfusion in Raynaud's phenomenon.
    Engelhart M; Seibold JR
    Angiology; 1990 Sep; 41(9 Pt 1):715-23. PubMed ID: 2221472
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effects of thromboxane receptor blockade on platelet aggregation and digital skin blood flow in patients with secondary Raynaud's syndrome.
    Lau CS; Khan F; McLaren M; Bancroft A; Walker M; Belch JJ
    Rheumatol Int; 1991; 11(4-5):163-8. PubMed ID: 1838424
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Digital blood flow measurement by venous occlusion plethysmography in Raynaud's phenomenon. Value of the rewarming test].
    Cristol R; Debray J
    J Mal Vasc; 1986; 11(1):85-9. PubMed ID: 3944527
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased whole blood platelet aggregation in patients with Raynaud's phenomenon with or without systemic sclerosis.
    Lau CS; McLaren M; Saniabadi A; Belch JJ
    Scand J Rheumatol; 1993; 22(3):97-101. PubMed ID: 8316776
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of digital artery adrenoceptors in Raynaud's disease.
    Cooke JP; Creager SJ; Scales KM; Ren C; Tsapatsaris NP; Beetham WP; Creager MA
    Vasc Med; 1997; 2(1):1-7. PubMed ID: 9546943
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acute effect of topical minoxidil on digital blood flow in patients with Raynaud's phenomenon.
    Whitmore SE; Wigley FM; Wise RA
    J Rheumatol; 1995 Jan; 22(1):50-4. PubMed ID: 7699682
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selective antagonism of S2-serotonergic receptors relieves but does not prevent cold induced vasoconstriction in primary Raynaud's phenomenon.
    Seibold JR; Terregino CA
    J Rheumatol; 1986 Apr; 13(2):337-40. PubMed ID: 2941573
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma.
    Colakoğlu M; Cobankara V; Akpolat T
    Ann Pharmacother; 2007 Sep; 41(9):1544-7. PubMed ID: 17666574
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of cold and emotional stress in Raynaud's disease and scleroderma.
    Freedman RR; Ianni P
    Br Med J (Clin Res Ed); 1983 Nov; 287(6404):1499-502. PubMed ID: 6416474
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.